Literature DB >> 25935742

Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation.

Peter Steenbergen1, Karin Haustermans2, Evelyne Lerut3, Raymond Oyen4, Liesbeth De Wever4, Laura Van den Bergh2, Linda G W Kerkmeijer5, Frank A Pameijer6, Wouter B Veldhuis6, Jochem R N van der Voort van Zyp5, Floris J Pos1, Stijn W Heijmink7, Robin Kalisvaart1, Hendrik J Teertstra7, Cuong V Dinh1, Ghazaleh Ghobadi1, Uulke A van der Heide8.   

Abstract

BACKGROUND AND
PURPOSE: Boosting the dose to the largest (dominant) lesion in radiotherapy of prostate cancer may improve treatment outcome. The success of this approach relies on the detection and delineation of tumors. The agreement among teams of radiation oncologists and radiologists delineating lesions on multiparametric magnetic resonance imaging (mp-MRI) was assessed by measuring the distances between observer contours. The accuracy of detection and delineation was determined using whole-mount histopathology specimens as reference.
MATERIAL AND METHODS: Six observer teams delineated tumors on mp-MRI of 20 prostate cancer patients who underwent a prostatectomy. To assess the inter-observer agreement, the inter-observer standard deviation (SD) of the contours was calculated for tumor sites which were identified by all teams.
RESULTS: Eighteen of 89 lesions were identified by all teams, all were dominant lesions. The median histological volume of these was 2.4cm(3). The median inter-observer SD of the delineations was 0.23cm. Sixty-six of 69 satellites were missed by all teams.
CONCLUSION: Since all teams identify most dominant lesions, dose escalation to the dominant lesion is feasible. Sufficient dose to the whole prostate may need to be maintained to prevent under treatment of smaller lesions and undetected parts of larger lesions.
Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Dose escalation; Inter-observer variability; Multiparametric MRI; Prostate cancer; Radiotherapy; Tumor delineation

Mesh:

Year:  2015        PMID: 25935742     DOI: 10.1016/j.radonc.2015.04.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  28 in total

1.  Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer.

Authors:  Cédric Draulans; Robin De Roover; Uulke A van der Heide; Linda Kerkmeijer; Robert J Smeenk; Floris Pos; Wouter V Vogel; James Nagarajah; Marcel Janssen; Sofie Isebaert; Frederik Maes; Cindy Mai; Raymond Oyen; Steven Joniau; Martina Kunze-Busch; Karolien Goffin; Karin Haustermans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-06       Impact factor: 9.236

2.  CNN-based hierarchical coarse-to-fine segmentation of pelvic CT images for prostate cancer radiotherapy.

Authors:  Sharmin Sultana; Adam Robinson; Daniel Y Song; Junghoon Lee
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2020-03-16

3.  Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.

Authors:  J V Hegde; D J Margolis; P-C Wang; R E Reiter; J Huang; M L Steinberg; M Kamrava
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-31       Impact factor: 5.554

4.  Automatic Segmentation of Clinical Target Volume and Organs-at-Risk for Breast Conservative Radiotherapy Using a Convolutional Neural Network.

Authors:  Fangjie Liu; Wanqi Chen; Zhikai Liu; Yinjie Tao; Xia Liu; Fuquan Zhang; Jing Shen; Hui Guan; Hongnan Zhen; Shaobin Wang; Qi Chen; Yu Chen; Xiaorong Hou
Journal:  Cancer Manag Res       Date:  2021-11-02       Impact factor: 3.989

5.  MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.

Authors:  Almudena Zapatero; Maria Roch; Pablo Castro Tejero; David Büchser; Carmen Martin de Vidales; Saturnino González; Pablo Rodríguez; Luis Alberto San Jose; Guillermo Celada; Maria Teresa Murillo
Journal:  Br J Radiol       Date:  2021-09-19       Impact factor: 3.039

6.  Predicting Biochemical Failure in Irradiated Patients With Prostate Cancer by Tumour Volume Measured by Multiparametric MRI.

Authors:  Benedict Oerther; Moritz V Buren; Christina M Klein; Simon Kirste; Nils H Nicolay; Tanja Sprave; Simon Spohn; Deepa Darshini Gunashekar; Leonard Hagele; Lars Bielak; Michael Bock; Anca-L Grosu; Fabian Bamberg; Matthias Benndorf; Constantinos Zamboglou
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

7.  Prostate cancer GTV delineation with biparametric MRI and 68Ga-PSMA-PET: comparison of expert contours and semi-automated methods.

Authors:  Nathan Hearn; John Blazak; Philip Vivian; Dinesh Vignarajah; Katelyn Cahill; Daisy Atwell; Jim Lagopoulos; Myo Min
Journal:  Br J Radiol       Date:  2021-01-28       Impact factor: 3.039

Review 8.  Ultrasound Elastography of the Prostate Using an Unconstrained Modulus Reconstruction Technique: A Pilot Clinical Study.

Authors:  Seyed Reza Mousavi; Hassan Rivaz; Gregory J Czarnota; Abbas Samani; Ali Sadeghi-Naini
Journal:  Transl Oncol       Date:  2017-07-20       Impact factor: 4.243

9.  Template guided transperineal saturation biopsy of the prostate: lessons for focal and urethra-sparing high-dose-rate brachytherapy for localized prostate cancer.

Authors:  Sergey Nikolaevich Novikov; Sergey Vasilevich Kanaev; Roman Vladimirovich Novikov; Nikolay Dmitrievich IIlin; Anna Sergeevna Artemieva; Alexnder Olegovich Ivantcov; Evgeniy Alexandrovich Piskunov; Mariya Yurievna Gotovchikova
Journal:  J Contemp Brachytherapy       Date:  2016-04-19

Review 10.  Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers.

Authors:  Alexandru Mihai Nicolae; Niranjan Venugopal; Ananth Ravi
Journal:  Cancer Nanotechnol       Date:  2016-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.